SARS-CoV-2 Vaccines: Status Report

Fatima Amanat, Florian Krammer

Research output: Contribution to journalReview articlepeer-review

838 Scopus citations

Abstract

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.

Original languageEnglish
Pages (from-to)583-589
Number of pages7
JournalImmunity
Volume52
Issue number4
DOIs
StatePublished - 14 Apr 2020

Fingerprint

Dive into the research topics of 'SARS-CoV-2 Vaccines: Status Report'. Together they form a unique fingerprint.

Cite this